SIP
DYN icon

Stoneridge Investment Partners’s Dyne Therapeutics DYN Stock Holding History

Stoneridge Investment Partners’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,611
Closed -$301K – 161
2026
Q1 		$301K Buy
+16,611
New +$286K 0.22% 86

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Stoneridge Investment Partners's DYN Position: Q2 2026 in Review

Stoneridge Investment Partners sold out of Dyne Therapeutics (DYN) in Q2 2026, closing a stake of 16,611 shares — an estimated $301K sold.

Stoneridge Investment Partners first reported a position in DYN in Q1 2026 and held it in 1 quarter. The position peaked at $301K in Q1 2026. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Stoneridge Investment Partners reported no remaining Dyne Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Stoneridge Investment Partners sold 16,611 Dyne Therapeutics shares in Q2 2026, an estimated $301K.
  • Stoneridge Investment Partners first reported a position in Dyne Therapeutics in Q1 2026 and held it in 1 quarter.
  • Stoneridge Investment Partners's Dyne Therapeutics position peaked at $301K in Q1 2026.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Stoneridge Investment Partners's 13F filing for Q2 2026, filed 6 Aug 2026.